{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:29:48Z","timestamp":1788532188588,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To describe the 12-month Clinical Disease Activity Index (CDAI) trajectory patterns and their determinants in patients with rheumatoid arthritis (RA) treated with subcutaneous abatacept.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a post hoc analysis of adult patients with RA from the Abatacept Best Care (ABC) study. A growth mixture model (GMM) with Bayesian imputation for missing endpoints was used to define CDAI trajectory groups over 12 months. Determinants of trajectory patterns were identified among baseline patient and disease characteristics using bivariate comparisons and multivariable logistic regression with stepwise selection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      For the overall study sample (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009256) mean (SD) age was 60.1 (11.5) years, 191 (75%) were female, and baseline CDAI was 30.1 (10.6). The GMM identified 3 trajectory groups that were classified as Rapid Responders (RR;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009125 [49%]), Late Responders (LR;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200996 [38%]), and Non-Responders (NR;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200935 [14%]). RR had lower baseline CDAI, Disease Activity Score 28 - C-Reactive Protein, Patient Global Assessment (PtGA), Routine Assessment of Patient Index Data 3, Simplified Disease Activity Index, and Tender Joint Count compared to LR and NR (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Lower baseline PtGA, Rheumatic Disease Comorbidity Index, and lack of prior biologic use were significant predictors of RR (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.03). CDAI scores at 3 months were not predictive of 12-month response to treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Approximately 85% of the abatacept-treated patients with RA in this study showed Rapid or Late CDAI reduction over 12 months. Trajectory-based analyses are informative and may have implications for clinical practice and research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>This study was registered on 06 September 2017 in ClinicalTrials.gov under the registration number NCT03274141.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42358-026-00554-y","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:26:05Z","timestamp":1782210365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CDAI trajectories in patients with rheumatoid arthritis treated with abatacept in real-world"],"prefix":"10.1186","volume":"66","author":[{"given":"Janet E.","family":"Pope","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Sampalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boulos","family":"Haraoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Rampakakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Allum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Olivier","family":"Trepanier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6834-2731","authenticated-orcid":false,"given":"Louis","family":"Bessette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"554_CR1","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: A review. JAMA. 2018;320:1360\u201372.","journal-title":"JAMA"},{"key":"554_CR2","doi-asserted-by":"publisher","first-page":"Itc1","DOI":"10.7326\/AITC201901010","volume":"170","author":"JA Sparks","year":"2019","unstructured":"Sparks JA. Rheumatoid Arthritis. Ann Intern Med. 2019;170:Itc1\u201316.","journal-title":"Ann Intern Med"},{"key":"554_CR3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13075-023-03151-2","volume":"25","author":"L Bessette","year":"2023","unstructured":"Bessette L, Haraoui B, Rampakakis E, et al. Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abatacept. Arthritis Res Ther. 2023;25:183.","journal-title":"Arthritis Res Ther"},{"key":"554_CR4","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40265-017-0775-4","volume":"77","author":"HA Blair","year":"2017","unstructured":"Blair HA, Deeks ED. Abatacept: A review in rheumatoid arthritis. Drugs. 2017;77:1221\u201333.","journal-title":"Drugs"},{"key":"554_CR5","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/acr.22763","volume":"68","author":"R Fleischmann","year":"2016","unstructured":"Fleischmann R, Weinblatt ME, Schiff M, et al. Patient-reported outcomes from a two-year head-to-head comparison of subcutaneous abatacept and adalimumab for rheumatoid arthritis. Arthritis Car Res (Hoboken). 2016;68:907\u201313.","journal-title":"Arthritis Car Res (Hoboken)"},{"key":"554_CR6","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3899\/jrheum.170344","volume":"45","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Pacheco-Tena C, Covarrubias A, et al. Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial. J Rheumatol. 2018;45:1085\u201392.","journal-title":"J Rheumatol"},{"key":"554_CR7","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1136\/ard.2007.080002","volume":"67","author":"M Schiff","year":"2008","unstructured":"Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67:1096\u2013103.","journal-title":"Ann Rheum Dis"},{"key":"554_CR8","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1007\/s10067-022-06176-1","volume":"41","author":"R Alten","year":"2022","unstructured":"Alten R, Mariette X, Flipo RM, et al. Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study. Clin Rheumatol. 2022;41:2361\u201373.","journal-title":"Clin Rheumatol"},{"key":"554_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","volume":"74","author":"P Emery","year":"2015","unstructured":"Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015;74:19\u201326.","journal-title":"Ann Rheum Dis"},{"key":"554_CR10","doi-asserted-by":"publisher","first-page":"e000564","DOI":"10.1136\/rmdopen-2017-000564","volume":"4","author":"D Jansen","year":"2018","unstructured":"Jansen D, Emery P, Smolen JS, et al. Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study. RMD Open. 2018;4:e000564.","journal-title":"RMD Open"},{"key":"554_CR11","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ebiom.2016.08.024","volume":"11","author":"DS Courvoisier","year":"2016","unstructured":"Courvoisier DS, Alpizar-Rodriguez D, Gottenberg JE, et al. Rheumatoid arthritis patients after initiation of a new biologic agent: trajectories of disease activity in a large multinational cohort study. EBioMedicine. 2016;11:302\u20136.","journal-title":"EBioMedicine"},{"key":"554_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/03009742.2019.1627411","volume":"49","author":"Y Endo","year":"2020","unstructured":"Endo Y, Koga T, Kawashiri SY, et al. Anti-citrullinated protein antibody titre as a predictor of abatacept treatment persistence in patients with rheumatoid arthritis: a prospective cohort study in Japan. Scand J Rheumatol. 2020;49:13\u20137.","journal-title":"Scand J Rheumatol"},{"key":"554_CR13","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s10067-019-04449-w","volume":"38","author":"R Alten","year":"2019","unstructured":"Alten R, Mariette X, Lorenz HM, et al. Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study. Clin Rheumatol. 2019;38:1413\u201324.","journal-title":"Clin Rheumatol"},{"key":"554_CR14","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/art.39595","volume":"68","author":"JE Gottenberg","year":"2016","unstructured":"Gottenberg JE, Courvoisier DS, Hernandez MV, et al. Brief report: Association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: Results from the Pan-European registry analysis. Arthritis Rheumatol. 2016;68:1346\u201352.","journal-title":"Arthritis Rheumatol"},{"key":"554_CR15","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1136\/annrheumdis-2017-211430","volume":"77","author":"K Oryoji","year":"2018","unstructured":"Oryoji K, Yoshida K, Kashiwado Y, et al. Shared epitope positivity is related to efficacy of abatacept in rheumatoid arthritis. Ann Rheum Dis. 2018;77:1234\u20136.","journal-title":"Ann Rheum Dis"},{"key":"554_CR16","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40744-022-00529-7","volume":"10","author":"PC Taylor","year":"2023","unstructured":"Taylor PC, Chen YF, Pope J, et al. Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies. Rheumatol Ther. 2023;10:463\u201376.","journal-title":"Rheumatol Ther"},{"key":"554_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/acr.22175","volume":"66","author":"L Siemons","year":"2014","unstructured":"Siemons L, Ten Klooster PM, Vonkeman HE, et al. Distinct trajectories of disease activity over the first year in early rheumatoid arthritis patients following a treat-to-target strategy. Arthritis Car Res (Hoboken). 2014;66:625\u201330.","journal-title":"Arthritis Car Res (Hoboken)"},{"key":"554_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1751-0473-3-17","volume":"3","author":"Z Bursac","year":"2008","unstructured":"Bursac Z, Gauss CH, Williams DK, et al. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3:17.","journal-title":"Source Code Biol Med"},{"key":"554_CR19","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1136\/ard.2008.101121","volume":"68","author":"R Westhovens","year":"2009","unstructured":"Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;68:1870\u20137.","journal-title":"Ann Rheum Dis"},{"key":"554_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/art.37711","volume":"65","author":"ME Weinblatt","year":"2013","unstructured":"Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013;65:28\u201338.","journal-title":"Arthritis Rheum"},{"key":"554_CR21","doi-asserted-by":"publisher","first-page":"e000345","DOI":"10.1136\/rmdopen-2016-000345","volume":"3","author":"R Alten","year":"2017","unstructured":"Alten R, Nusslein HG, Mariette X, et al. Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naive: 6-month results from a real-world, international, prospective study. RMD Open. 2017;3:e000345.","journal-title":"RMD Open"},{"key":"554_CR22","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","volume":"403","author":"AP Cope","year":"2024","unstructured":"Cope AP, Jasenecova M, Vasconcelos JC, et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet. 2024;403:838\u201349.","journal-title":"Lancet"},{"key":"554_CR23","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S0140-6736(23)02650-8","volume":"403","author":"J Rech","year":"2024","unstructured":"Rech J, Tascilar K, Hagen M, et al. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet. 2024;403:850\u20139.","journal-title":"Lancet"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-026-00554-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-026-00554-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-026-00554-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:11:12Z","timestamp":1788531072000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42358-026-00554-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["554"],"URL":"https:\/\/doi.org\/10.1186\/s42358-026-00554-y","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ABC study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice Guidelines. The study protocol and patient enrolment materials were approved by local ethics committees and regulatory agencies prior to initiation of the study. All patients gave written informed consent before any study-related procedures were performed.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"54"}}